<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289831</url>
  </required_header>
  <id_info>
    <org_study_id>03027612</org_study_id>
    <nct_id>NCT04289831</nct_id>
  </id_info>
  <brief_title>Preoperative Biliary Drainage in Patients With Operable Malignant Periampulary Tumors</brief_title>
  <official_title>&quot;Impact of Preoperative Biliary Drainage on Surgical and Oncologic Outcomes After Pancreatico-Duodenectomy in Patients With Operable Malignant Periampulary Tumors. A Randomized Controlled Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alexandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alexandria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact of preoperative biliary drainage (PBD) on morbidity and mortality associated with
      Pancreaticoduodenectomy (PD) in patients with peri-ampulary tumors is still controversial.
      The objective of this study is to evaluate the impact of PBD on surgical and oncologic
      outcomes after PD in jaundiced patients with operable peri-ampulary tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      150 consecutive jaundiced patients with suspected operable peri-ampullary tumors were
      randomized via concealed envelopes into 2 groups (each included 75 patients), group I managed
      by direct surgery while group II managed by PBD followed by surgery. Both groups were
      compared regarding perioperative mortality, morbidities, tumor recurrence and 2 years
      survival rates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early postoperative mortality (within 3 months)</measure>
    <time_frame>within 90 days after surgery</time_frame>
    <description>Death within 90 days postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early postoperative morbidities (within 3 months)</measure>
    <time_frame>within 90 days after surgery</time_frame>
    <description>Any complications related to surgery within 3 months including: postoperative bleeding, pancreatic fistula, Biliary leakage, Intra-abdominal infection, wound infection/ dehiscence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor recurrence</measure>
    <time_frame>2 years follow up after surgery</time_frame>
    <description>Local or systemic recurrence of the malignant tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>2 years follow up after surgery</time_frame>
    <description>% of patients survived without any evidence of tumor recurrence after 2 years follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years follow up after surgery</time_frame>
    <description>% of patients survived with or without tumor recurrence after 2 years follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Periampullary Cancer</condition>
  <condition>Biliary Obstruction</condition>
  <condition>Preoperative Biliary Drainage</condition>
  <arm_group>
    <arm_group_label>Direct Surgery (DS) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients subjected to direct surgery (DS) within 1 week after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative Biliary Drainage (PBD) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients managed by Preoperative Biliary Drainage followed by surgery after 4-6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preoperative Biliary Drainage (PBD)</intervention_name>
    <description>Endoscopic retrograde biliary drainage (ERBD) and stent placement was the first choice for PBD while ultrasound-guided percutaneous transhepatic biliary drainage (PTBD) was done if ERBD was not feasible. Biliary drainage was considered successful if the serum bilirubin level decreased by 50% or more within 2 weeks after the procedure. Patients with failed PBD were referred directly to surgery, while those with successful PBD were referred to surgery 4 to 6 weeks after first drainage procedure according to the latest guidelines</description>
    <arm_group_label>Preoperative Biliary Drainage (PBD) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>The standard surgical procedure for operable tumors Whipple procedure with triple reconstruction, namely pancreatogastrostomy or pancreatojejunostomy,hepaticojejunostomy and gastrojejunostomy</description>
    <arm_group_label>Direct Surgery (DS) group</arm_group_label>
    <arm_group_label>Preoperative Biliary Drainage (PBD) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum bilirubin level above 4 mg/dl

          -  suspected peri-ampullary tumor at computed tomography (CT)

          -  No evidence of distant metastasis or locally advanced tumor

        Exclusion Criteria:

          -  Patients with evidence of distant metastasis or locally advanced tumor

          -  Prior neoadjuvant chemotherapy or Radiotherapy

          -  Prior biliary surgery

          -  Patients with contraindication for major surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed M Elmessiry, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ass. Professor of Surgery (Surgical Oncology Unit)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eman A Mohamed, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of Internal Medicine (Gastroenterology Unit)</affiliation>
  </overall_official>
  <reference>
    <citation>Wang C, Xu Y, Lu X. Should preoperative biliary drainage be routinely performed for obstructive jaundice with resectable tumor? Hepatobiliary Surg Nutr. 2013 Oct;2(5):266-71. doi: 10.3978/j.issn.2304-3881.2013.09.01. Review.</citation>
    <PMID>24570957</PMID>
  </reference>
  <reference>
    <citation>Mezhir JJ, Brennan MF, Baser RE, D'Angelica MI, Fong Y, DeMatteo RP, Jarnagin WR, Allen PJ. A matched case-control study of preoperative biliary drainage in patients with pancreatic adenocarcinoma: routine drainage is not justified. J Gastrointest Surg. 2009 Dec;13(12):2163-9. doi: 10.1007/s11605-009-1046-9. Epub 2009 Sep 23.</citation>
    <PMID>19774424</PMID>
  </reference>
  <reference>
    <citation>Smith RA, Dajani K, Dodd S, Whelan P, Raraty M, Sutton R, Campbell F, Neoptolemos JP, Ghaneh P. Preoperative resolution of jaundice following biliary stenting predicts more favourable early survival in resected pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2008 Nov;15(11):3138-46. doi: 10.1245/s10434-008-0148-z. Epub 2008 Sep 12.</citation>
    <PMID>18787902</PMID>
  </reference>
  <reference>
    <citation>Abdullah SA, Gupta T, Jaafar KA, Chung YF, Ooi LL, Mesenas SJ. Ampullary carcinoma: effect of preoperative biliary drainage on surgical outcome. World J Gastroenterol. 2009 Jun 21;15(23):2908-12.</citation>
    <PMID>19533815</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Mohamed El Messiry</investigator_full_name>
    <investigator_title>Ass. Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

